Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Expert Rev Gastroenterol Hepatol. 2012 Dec;6(6):659-65. doi: 10.1586/egh.12.53.
Ulcerative colitis is a chronic, idiopathic, inflammatory disease of the colon and rectum that may be associated with growth failure, nutritional derangements and psychosocial ramifications in affected children. Multiple medical options are available to achieve disease remission; however, some of these medications can have unwanted side effects, especially in younger patients. With increased understanding of the etiology of the disease, newer therapeutic alternatives have arisen in the form of biologic therapies, namely monoclonal antibodies targeted to a specific protein or receptor. Specifically, infliximab, an anti-TNF-α agent, has been shown to be safe and effective for the treatment of moderate-to-severe pediatric ulcerative colitis.
溃疡性结肠炎是一种慢性、特发性、炎症性疾病，可发生于结肠和直肠，可能与受影响儿童的生长发育迟缓、营养失调和心理社会后果有关。有多种医学选择可实现疾病缓解；然而，其中一些药物可能会产生不良副作用，尤其是在年轻患者中。随着对疾病病因的认识不断增加，以生物疗法为形式的新的治疗选择已经出现，即针对特定蛋白质或受体的单克隆抗体。具体来说，抗 TNF-α 药物英夫利昔单抗已被证明对治疗中度至重度儿童溃疡性结肠炎是安全有效的。
